How this fits in

Selective oestrogen receptor modulators (SERMs) have been demonstrated to reduce the risk of developing breast cancer in women who are at increased risk, and Australian guidelines recommend that GPs consider prescribing SERMs for eligible patients. However, SERMs increase the risk of developing uterine cancer (tamoxifen), blood clots (tamoxifen and raloxifene), and menopausal symptoms (tamoxifen and raloxifene), so an understanding of the balance of harms and benefits is needed to make an informed decision. This study explored established and novel ways of presenting the harms and benefits of taking SERMs to reduce breast cancer risk, and evaluated the response women have to the different risk formats, and different medications, at different levels of hypothetical risk.